Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.

Abstract: A method and system process a test signal in medical domain by:—acquiring an input digital signal F(t) as a function of time t in the form of two-dimensional data, said signal F(t) resulting from the excitation, within a test substrate, of a substance adapted to emit a signal in response to said excitation;—modeling said input digital signal F(t) in function of a pre-established model;—possibly, generating an output digital signal I(t) made up from said modeling; wherein said modeling is based on the following model: (formula I) where the coefficients a0, a1, a2, p, q, A and B are estimated on the basis of said two-dimensional data. The method and system are directed to the tumoral vascularization or tumoral angiogenesis detection in tumors.

Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.

Abstract: The invention relates to a method and system for processing a test signal in medical domain comprising following steps:—acquiring (110, 120, 130) an input digital signal F(t) function of time t in the form of two-dimensional data (t, F(t)), said signal F(t) resulting from the excitation, within a test substrate, of a substance adapted to emit a signal in response to said excitation;—modeling (140) said input digital signal F(t) in function of a pre-established model;—possibly, generating an output digital signal I(t) made up from said modeling; wherein said modeling is based on the following model: (formula I) where the coefficients a0, a1, a2, p, q, A et B are estimated on the basis of said two-dimensional data. The invention is directed to the tumoral vascularization or tumoral angiogenesis detection in tumors.

Abstract: A pharmaceutical composition for the treatment, prevention or diagnosis of a tumoral pathology comprising an active agent which stabilizes an actin network of a cellular cytoskeleton.

Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.

Abstract: A pharmaceutical composition for the treatment, prevention or diagnosis of a tumoral pathology comprising an active agent which stabilizes an actin network of a cellular cytoskeleton.

Abstract: A molecule binding to a target including an EP motif having the following sequence: (X-(EP)n-Y-(EP)m-Z)p wherein X, Y and Z may be identical or different and include a sequence of 0 to 10 amino acids, identical or different, n and m are integers between 0 to 20, preferably between 3 to 10, with at least one of n or m being different from 0, and p is an integer between 1 and 10.